remedē®

PATIENT AMBASSADOR PROFILE



Patient Story

Patient Name: Pastor Glenn Myers

Spouse/Caregiver: Susan

Date of remedē implant: March 17, 2014

Patient Story: I was diagnosed with Central Sleep Apnea (CSA) in 2013 after completing a sleep study. I was TIRED ALL THE TIME and had frequent headaches. Throughout the night, my wife Susan would periodically wake up and not hear me breathing. I was falling asleep during the day at the most inconvenient times, like when visiting with parish members. Even more concerning was the fact that I would get dangerously sleepy while driving. Coffee and caffeine became not only a morning drink, but a necessity to stay awake throughout the day.

While at the cardiologist's office for my atrial fibrillation, I learned of a new implantable device called **rem**edē® that was in the research phase and was discussed as a possible treatment option for my CSA. In March of 2014, I was the first recipient to receive the **rem**edē device at Forsyth Medical Center as part of the clinical trial. I was randomly chosen to be in the "control" group of the research study, which meant that the device would not be activated for six months. Thankfully, the **rem**edē device was activated in October 2014 and I received immediate benefit, with much improved sleep and less apneas throughout the night. The bags under my eyes are much less noticeable and my daytime sleepiness has greatly lessened. Decaf coffee is now the norm. Daily morning and evening walks, along with a full work schedule, is my normal way of life now! The headaches are gone, and the old Glenn is back!!! My wife and I are so thankful for this life saving device and for all of those who introduced us to Respicardia and the **rem**edē System.

Patient Activity Level/Hobbies/Pastimes: Glenn's activity levels have increased significantly. Glenn and his wife enjoy daily walks to stay healthy. Glenn still greatly enjoys his pastoral work, but he and his wife are excited about the future as they look forward to traveling the world as they transition into retirement.

Medical Summary

Patient Age: 66

Date of CSA Diagnosis: February 28, 2014

Medical Team

Referring Center: Novant Forsyth Medical Center

Sleep Center: Novant Forsyth Sleep Center

Implanting Center: Novant Forsyth Medical Center

Pre- and Post- remedē Sleep Metrics*

Before remedē Therapy

Apnea Hypopnea Index (AHI): **27.3/hr**

Central Apnea Index (CAI): **15.9/hr**

After 5 Years of remedē Therapy

Apnea Hypopnea Index (AHI): **2.1/hr**

Central Apnea Index (CAI): **0.0/hr**

Sleep data obtained from patient sleep studies administered before and after **remedē System treatment.*

ZOLL®

The account given is genuine and documented.

Each story represents a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to the therapy.

The table below provides median change in AHI and CAI from the **rem**edē Pivotal Trial. Individual patient results may vary.

	BASELINE (N=131)	1 YEAR (N=115)	2 YEARS (N=101)	5 YEARS (N=42)
Apnea Hypopnea Index (AHI)	**46** [34, 60]	**18** [9, 34]	**16** [7, 32]	**17** [9, 34]
Central Apnea Index (CAI)	**23** [13, 39]	**1** [0, 4]	**1** [0, 3]	**1** [0, 5]

Reported as median [interquartile range].

Please speak with your doctor to determine if this therapy is right for you.
Full Important Safety Information can be found at remede.zoll.com.

Important Safety Information
The **rem**edē® System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. Your doctor will need to evaluate your condition to determine if the **rem**edē System is right for you. You will not be able to have an MRI or diathermy (special heat therapies) if you have the **rem**edē System implanted. The **rem**edē System may be used if you have another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The **rem**edē System may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required. Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the **rem**edē System. For further information, please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Indication for use:** The **rem**edē System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe Central Sleep Apnea (CSA) in adult patients. **Contraindications:** The **rem**edē System is contraindicated for use in patients with an active infection or patients known to require magnetic resonance imaging (MRI). See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events. **Rx Only.**
The **rem**edē® System, **rem**edē® EL System, and **rem**edē® EL-X System have received FDA approval. The **rem**edē® System model 1001 has received CE Mark approval.

ZOLL MEDICAL CORPORATION

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 | 952-540-4470 | info@remede.zoll.com | remede.zoll.com

For subsidiary addresses and fax numbers, as well as other global locations, please go to www.zoll.com/contacts.

Printed in the U.S.A.
PAP2322, Rev C